

a1
sub B1
polypeptides and fibronectin polypeptides [a polypeptide or a small molecule] capable of binding to the α_4 subunit of VLA-4, [or combinations of any of the foregoing,] in an amount effective to treat [provide inhibition of onset of] diabetes.

a2
sub B2
~~15.~~ (Amended) A method according to claim ~~10~~, wherein the composition comprises [a plurality of] anti-VLA-4 monoclonal antibodies or VLA-4-binding fragments thereof.

~~16.~~ (Amended) A method according to claim 10, wherein the composition is administered at a dosage so as to provide from about 0.1 to about 10 mg/kg of antibody, antibody fragment, [polypeptide or small molecule,] based on the weight of the susceptible mammal.

sub D1
a3
~~18.~~ (Amended) A method according to claim ~~10~~, wherein the composition is administered in an amount effective to provide a plasma level of antibody or ~~antibody fragment~~ in the mammal of at least 1 $\mu\text{g/ml}$ over a period of 1-14 days. *D1*

Please cancel claims 11 and 19-20.

Please add new claims 25-29.

sub B3
~~25.~~ (New) A method according to claim 10, wherein the composition comprises an antibody or fragments of such antibodies capable of binding to the α_4 subunit of VLA-4.

a4
~~26.~~ (New) A method according to claim ~~10~~, wherein the composition comprises a soluble VCAM-1 polypeptide capable of binding to the α_4 subunit of VLA-4.

[
~~27.~~ (New) A method according to claim 10, wherein the composition comprises a fibronectin polypeptide capable of binding to the α_4 subunit of VLA-4.

~~28.~~ (New) A method according to claim ~~10~~, wherein the antibody is a recombinant antibody.